DelveInsight’s “PD-1 and PD-L1 Inhibitors Competitive landscape 2025” report provides comprehensive insights about 180+ companies and 200+ drugs in the PD-1 and PD-L1 Inhibitors Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the full insights into the evolving PD-1 and PD-L1 Inhibitors Pipeline and discover which companies are leading the innovation race @ PD-1 and PD-L1 Inhibitors Competitive Landscape Report
Key Takeaways from the PD-1 and PD-L1 Inhibitors Report
- On 28 August 2025, AstraZeneca conducted a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following platinum based chemotherapy and anti-PD-1/anti-PD-L1 therapy.
- DelveInsight’s PD-1 and PD-L1 Inhibitors competitive landscape report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for PD-1 and PD-L1 Inhibitors treatment.
- The leading PD-1 and PD-L1 Inhibitors Companies such as GSK, Roche, Merck, Pfizer, CStone Pharmaceuticals, AstraZeneca, Incyte Corporation, Agenus, ImmVira Pharma, and Suzhou Zelgen Biopharmaceuticals and others.
- Promising PD-1 and PD-L1 Inhibitors Therapies such as Zalifrelimab, Isunakinra, Vopratelimab, Ipilimumab, Pembrolizumab, Regorafenib (Stivarga, BAY73-4506), Nivolumab, Paclitaxel, and others.
Unlock detailed analysis of the PD-1 and PD-L1 Inhibitors Competitive Landscape 2025 and identify key growth opportunities @ PD-1 and PD-L1 Inhibitors Research and Development Report
PD-1 and PD-L1 Inhibitors Marketed Therapies
- Merck
Merck & Co., Inc., known as MSD outside the United States and Canada, is a global healthcare company headquartered in Rahway, New Jersey. The company is engaged in the research, development, manufacture, and marketing of a broad range of pharmaceutical products, vaccines, and animal health solutions. Merck is widely recognized for its contributions in oncology, particularly through its immunotherapy drug Keytruda, as well as for its efforts in infectious diseases, cardiometabolic conditions, and vaccines. With a strong commitment to scientific innovation and global health, Merck invests heavily in R&D and pursues strategic partnerships to address some of the world’s most pressing health challenges.
- KEYTRUDA
Pembrolizumab is the active ingredient of Keytruda, which is a humanized monoclonal antibody that binds to the programmed cell death – 1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including anti-tumor immune response. Pembrolizumab is an IgG4 kappa immunoglobulin and has an approximate 149 kDa molecular weight. Keytruda has received approval for advanced melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer, classical Hodgkin lymphoma, microsatellite-instability-high cancer, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Small Cell Lung Cancer (SCLC), Microsatellite Instability-High Cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Renal Cell Carcinoma, Endometrial Carcinoma and advanced urothelial bladder cancer.
- GSK
GSK (GlaxoSmithKline) is a global biopharmaceutical company focused on developing innovative medicines and vaccines to improve health outcomes worldwide. With a strong presence in infectious diseases, HIV, oncology, immunology, and respiratory conditions, GSK leverages cutting-edge science and advanced technology to deliver transformative healthcare solutions. The company combines a robust R&D pipeline with strategic collaborations to address some of the world’s most pressing health challenges, aiming to positively impact the lives of billions of people.
- JEMPERLI
Jemperli, a programmed death receptor-1 (PD-1)-blocking antibody, is the backbone of GSK’s ongoing immuno-oncology-based research and development programme. A robust clinical trial programme includes studies of Jemperli alone and in combination with other therapies in gynaecologic, colorectal and lung cancers, as well as where there are opportunities for transformational outcomes.
PD-1 and PD-L1 Inhibitors Pipeline Therapies
- AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom, specializing in the discovery, development, and commercialization of prescription medicines. The company focuses on three main therapy areas: oncology; cardiovascular, renal and metabolism (CVRM); and respiratory and immunology. AstraZeneca is also expanding its presence in rare diseases through its acquisition of Alexion Pharmaceuticals. With a strong commitment to innovation and sustainability, AstraZeneca invests significantly in R&D and leverages advanced technologies to accelerate drug development. The company operates in over 100 countries and aims to deliver life-changing medicines that improve patient outcomes globally.
- Rilvegostomig
Rilvegostomig (AZD-2936) is a bi-specific antibody acts by targeting T cell immunoreceptor with Ig and ITIM domains (TIGIT) and programmed cell death protein 1 (PD1). It is derived from COM902 (anti-TIGIT antibody). It is administered through Intravenous route.
Currently, the drug is in the Phase III stage of its development for the treatment of Biliary cancer. The drug is also under development for the treatment of solid tumors, advanced or metastatic squamous or non-squamous non-small cell lung carcinoma, squamous or non-squamous non-small cell lung cancer and locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, cholangiocarcinoma and gallbladder cancer.
- Pfizer
Pfizer Inc. is a global biopharmaceutical company headquartered in New York City, dedicated to discovering, developing, and delivering innovative medicines and vaccines. The company has a broad portfolio spanning oncology, immunology, rare diseases, inflammation, internal medicine, and vaccines. Pfizer gained worldwide recognition for its role in developing one of the first mRNA-based COVID-19 vaccines in partnership with BioNTech. Committed to improving global health, Pfizer invests significantly in research and development and actively engages in collaborations to advance science and expand access to its therapies across diverse markets.
- Sasanlimab
Sasanlimab is an investigational humanized IgG4 monoclonal antibody developed by Pfizer that targets programmed death-1 (PD-1), an immune checkpoint receptor expressed on T cells and other immune cells. By binding PD-1, sasanlimab blocks its interaction with PD-L1 and PD-L2, thereby restoring T-cell activation and enhancing anti-tumor immune responses. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Non-muscle Invasive Bladder Cancer.
- Incyte Corporation
Incyte Corporation is a biopharmaceutical company headquartered in Wilmington, Delaware, focused on the discovery, development, and commercialization of innovative therapeutics in oncology and inflammation. The company has established a diverse pipeline of small molecules and biologics, addressing both solid tumors and hematologic malignancies, as well as immune-mediated conditions. Incyte emphasizes precision medicine approaches, aiming to target disease mechanisms with greater specificity and efficacy. In addition to its in-house R&D capabilities, the company actively engages in strategic collaborations and licensing agreements to strengthen its portfolio and expand its global presence. Through continuous investment in science and innovation, Incyte strives to deliver meaningful therapeutic advances to patients worldwide.
- INCB 099280
INCB099280 is an orally administered small-molecule inhibitor of programmed cell death ligand 1 (PD-L1), developed by Incyte Corporation, designed to disrupt the PD-1/PD-L1 interaction, which is a key immune checkpoint pathway exploited by tumors to evade immune surveillance. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Cutaneous Squamous Cell Carcinoma.
- Suzhou Zelgen Biopharmaceuticals
Suzhou Zelgen Biopharmaceuticals is a China-based biopharmaceutical company focused on the research, development, and commercialization of innovative therapies across oncology, immunology, and hematology. The company integrates small molecules and biologics into its pipeline, targeting unmet medical needs with a focus on differentiated mechanisms of action. Zelgen follows a vertically integrated model, encompassing drug discovery, clinical development, manufacturing, and commercialization within China’s rapidly evolving healthcare landscape. With a commitment to scientific innovation and patient-centric development, the company aims to advance therapies that improve outcomes and expand treatment options in China and potentially global markets.
- ZG005
ZG005 is a bispecific monoclonal antibody developed by Suzhou Zelgen Biopharmaceuticals that targets both PD-1 and TIGIT immune checkpoints. This dual targeting aims to synergistically activate T cells and enhance the anti-tumor activity of natural killer (NK) cells, making it a promising immunotherapy for various solid tumors. ZG005 is currently being evaluated in Phase II for the treatment of Hepatocellular Carcinoma.
- ImmVira Pharma
ImmVira Pharma is a biotechnology company based in China that focuses on the development of next-generation oncolytic virus therapies for cancer treatment. The company leverages its proprietary OvPENS platform to design genetically engineered herpes simplex virus (HSV)-based therapies that selectively target and destroy tumor cells while stimulating anti-tumor immune responses. ImmVira’s pipeline includes candidates for a variety of solid tumors, including those with limited treatment options. By combining viral oncology with immunotherapy, the company aims to create potent, targeted therapies that enhance efficacy and safety in cancer care.
- C5252
Leveraging ImmVira's OvPENS development platform, MVR-C5252 is designed specifically for the treatment of malignant glioma. This product has been further genetically engineered on the basis of MVR-T3011 (also known as T3011) by specific attenuation to achieve on-target malignant gliocyte killing while maintaining safety profile. MVR-C5252 also carries exogenous genes that express IL-12 and PD-1 mAb to promote the immune response of tumor microenvironment for further anti-tumor activity. C5252 is currently being evaluated in Phase I for the treatment of Glioblastoma.
Gain strategic intelligence on PD-1 and PD-L1 Inhibitors Emerging Therapies, pipeline highlights, and competitive trends shaping the market @ PD-1 and PD-L1 Inhibitors Preclinical and Discovery Stage Products
PD-1 and PD-L1 Inhibitors Analytical Perspective by DelveInsight
In-depth Commercial Assessment: PD-1 and PD-L1 Inhibitors Collaboration Analysis by Companies
The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
PD-1 and PD-L1 Inhibitors Competitive Landscape
The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).
PD-1 and PD-L1 Inhibitors Report Assessment
- Company Analysis
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Stay informed on the latest advancements in PD-1 and PD-L1 Inhibitors Research and development—Download the in-depth pipeline and competitive landscape report @ PD-1 and PD-L1 Inhibitors Market Drivers and Barriers
Scope of the PD-1 and PD-L1 Inhibitors Pipeline Report
- Coverage- Global
- PD-1 and PD-L1 Inhibitors Companies- GSK, Roche, Merck, Pfizer, CStone Pharmaceuticals, AstraZeneca, Incyte Corporation, Agenus, ImmVira Pharma, and Suzhou Zelgen Biopharmaceuticals and others.
- PD-1 and PD-L1 Inhibitors Therapies- Zalifrelimab, Isunakinra, Vopratelimab, Ipilimumab, Pembrolizumab, Regorafenib (Stivarga, BAY73-4506), Nivolumab, Paclitaxel, and others.
- PD-1 and PD-L1 Inhibitors Marketed Therapies and Pipeline Therapies
- PD-1 and PD-L1 Inhibitors Preclinical and Discovery Stage Products, Unmet Needs
Understand the PD-1 and PD-L1 Inhibitors Companies, drugs, and market dynamics driving the PD-1 and PD-L1 Inhibitors Pipeline in 2025 @ PD-1 and PD-L1 Inhibitors Mechanism of Action and Unmet Needs
Table of Contents
- Introduction
- Executive Summary
- PD-1 and PD-L1 Inhibitors: Overview
- PD-1 and PD-L1 Inhibitors -Analytical Perspective: In-depth Commercial Assessment
- Competitive Landscape
- Therapeutic Assessment
- PD-1 and PD-L1 Inhibitors: Company and Product Profiles (Marketed Therapies)
- Merck
- Company Overview
- KEYTRUDA
- PD-1 and PD-L1 Inhibitors: Company and Product Profiles (Pipeline Therapies)
- Late Stage Products (Phase III)
- Comparative Analysis
- AstraZeneca
- Company Overview
- Rilvegostomig
- Mid Stage Products (Phase II)
- Comparative Analysis
- Suzhou Zelgen Biopharmaceuticals
- Company Overview
- ZG005
- Early Stage Products (Phase I)
- Comparative Analysis
- ImmVira Pharma
- Company Overview
- C5252
- Preclinical and Discovery Stage Products
- Company Name
- Product Name
- Inactive Products
- PD-1 and PD-L1 Inhibitors Unmet Needs
- PD-1 and PD-L1 Inhibitors Market drivers and barriers
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape